Health X Platform Q2: loss narrows 18% YoY to ₹12.7 Cr, swings from Q1 profit on MTM hit
PAT +17.57% YoY · revenue +60.68% · margins expanding
₹484.09 Cr
+60.68% YoY
₹-12.73 Cr
+17.57% YoY
-2.57%
+2.5pp YoY
₹-3.47
Health X Platform (formerly Sastasundar Ventures) posted consolidated revenue of ₹484.09 Cr, up 60.7% YoY and 8.3% QoQ, almost entirely on the Healthcare Network segment (RetailerShakti/SastaSundar e-commerce distribution), whose segment revenue rose to ₹486.22 Cr from ₹307.95 Cr a year ago. Consolidated net loss (after tax, including minority interests) was ₹12.73 Cr — narrower than the year-ago ₹15.44 Cr loss (-17.6% YoY, ~16.7% on an adjusted basis excluding a ₹0.17 Cr prior-year exceptional item) — but a reversal from Q1 FY27's thin ₹1.99 Cr profit. Loss attributable to owners was ₹11.04 Cr, basic EPS -₹3.47 (not annualised).
Q2 FY-2027 vs prior quarters
The QoQ swing was driven almost entirely by the Financial Services segment, which booked a ₹6.15 Cr mark-to-market LOSS on fair-value changes in its investment book this quarter versus a ₹6.33 Cr gain in Q1 FY27 — a roughly ₹12.5 Cr swing that accounts for nearly the entire sequential deterioration. The core Healthcare Network business actually kept improving: its own segment operating loss narrowed to ₹13.87 Cr from ₹14.87 Cr (QoQ) and ₹15.45 Cr (YoY) even as revenue grew. Consolidated NPM was -2.57% (vs -5.03% YoY, +0.43% in Q1 FY27) and OPM (segment EBIT margin) was -4.01% (vs -7.57% YoY, -1.96% QoQ) — margins improving YoY but compressing sequentially, purely on the investment-book swing.
The stock went into the print at ₹271.1, down 5.2% over the past month of trading.
For context: revenue is at a 6-quarter high.
What the summary numbers don't show
Standalone (holding-company-only) loss of ₹0.32 Cr on ₹0.09 Cr total income — nearly all business sits in subsidiaries
FY27 gross margin 8%+ target, approaching 12% at scale. RetailerShakti EBITDA positive expected Q3 FY27. July run rate ₹150 Cr. No EBITDA profitability for SastaSundar next 2-3 years.
No formal brokerage consensus for this quarter could be located for this micro-cap; third-party aggregators show FY27 consensus ROE near -13%, consistent with the company remaining loss-making. Management's prior concall (Aug 2026) guided RetailerShakti to turn EBITDA-positive in Q3 FY27 with a July run-rate of ₹150 Cr/month — this quarter's Healthcare Network revenue averaged roughly ₹162 Cr/month, slightly ahead of that marker, though the EBITDA milestone itself is a Q3 FY27 test not yet due. Management had separately flagged no EBITDA profitability for the core SastaSundar app for 2-3 years, consistent with the segment's continuing ₹13.87 Cr quarterly operating loss. The Board's June 2026 Composite Scheme of Arrangement amalgamating Microsec Resources, Innogrow Technologies and Sastasundar Healthbuddy into the company, effective April 1, 2026, remains pending regulatory approvals with no accounting impact yet reflected in this statement.
W1
RetailerShakti/Healthcare Network EBITDA-positive target guided for Q3 FY27 — segment still posting a ₹13.87 Cr operating loss this quarter
W2
Financial Services segment fair-value swings — a ₹12.5 Cr negative QoQ swing this quarter could reverse or repeat
W3
Composite Scheme of Arrangement (MRPL/ITL/SHBL amalgamation) approval status and its pro forma impact once accounted for
Standalone is holding-co only (Core Investment Company, interest income ₹0.07 Cr) — consolidated is the real business and primary basis. Consolidated PAT of -₹12.73 Cr includes NCI; owners' share is -₹11.04 Cr (EPS -₹3.47, not annualised). No exceptional item this quarter; year-ago quarter carried a ₹0.17 Cr impairment exceptional item at Genu Path Labs (immaterial — adjusted vs raw YoY PAT improvement ~16.7% vs 17.6%). Step-down subsidiary Genu Path Labs flagged going-concern by auditors (net worth fully eroded) but auditor calls it not material to the Group. patQoQPct omitted — Q1 FY27 PAT base (+₹1.99 Cr) is too small for a meaningful percentage swing to -₹12.73 Cr.